Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Zealand extends digital mammography:

This article was originally published in Clinica

Executive Summary

Digital mammography was praised by New Zealand's health minister Pete Hodgson at the opening of a NZ$3.8m (US$2.8m) facility in Dunedin (the second-largest city in the South Island) yesterday. It will be the country's second such facility. Benefits listed by Mr Hodgson include: shorter screening process; faster results; and electronically transferable images. Each year, New Zealand provides 150,000 free mammograms to women between the ages of 45-69 under the national programme BreastScreen Aotearoa, and the number of women getting screened is rising. Breast cancer deaths stand at around 630 annually, but Mr Hodgson said that screening reduces the chance of death for women between the ages of 45 and 69 by 20-35%. At the same launch event, a new mobile breast screening can was added to the programme's fleet of 10.

You may also be interested in...

QUOTED. 26 November 2020. Rachel Nuzum.

Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.

China Poised To Conditionally Approve First COVID Vaccine

The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts